Vericiguat for heart failure after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether the drug vericiguat helps people with heart failure after a heart attack. The trial looks at people whose heart pumping is weak and who have symptoms despite standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart attack more than 3 months ago.
- Your heart failure symptoms (like breathlessness or swelling) have been stable for at least one month.
- You are 18 years or older.
- Your heart failure is at a moderate to severe level (NYHA class II–IV).
- Your heart's pumping ability is reduced (LVEF 40% or less).
- A blood test shows a higher level of a heart stress marker (NT-proBNP).
- Your heart failure is caused by blocked arteries, not by other heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting the medication vericiguat soon after a heart attack can help people whose hearts are weakened (ejection fraction 45% or lower) and who developed heart failure. Vericiguat is an oral medicine that may reduce strain on the heart and improve outcomes when given early.
This study tests a medicine called vericiguat (a pill) to see if it can improve the heart's shape and function in people with heart failure and a weakened pump. You would keep taking your usual heart medications plus the study drug.
This study tests whether adding a new medicine called vericiguat to standard heart failure treatments helps patients with heart failure feel better and avoid hospital stays. Vericiguat is a pill that may improve heart function and reduce symptoms like shortness of breath and fatigue.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
This study tests a drug called vericiguat, which may help people with heart failure and a leaky tricuspid valve. It aims to improve heart function and reduce symptoms.
This trial tests if adding vericiguat to standard heart failure medicines helps people hospitalized with worsening heart failure. It's for those with a weak heart pump and high NT-proBNP levels.
Hear when a new HFrEF - Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.